Ódor Dorottya / EyeEmGetty Images
You might shrug off the idea of skin cancer and assume it won’t happen to you or if it does, you’ll just have a mole removed. No big deal, right?
Not so fast. Skin cancer is the most common cancer in the United States, and treatment may involve a lot more than a mole removal (a surgical procedure that may leave a scar), according to the American Academy of Dermatology (AAD).
“There’s nothing like having surgery on your face to make you really think,
Okay, what’s causing this, and what can I do to prevent anything going forward?” says Alysa Herman, M.D., a board-certified dermatologist practicing in Coral Gables, FL, and a spokesperson for The Skin Cancer Foundation.
Share this article
Share this article
MIAMI BEACH, Fla., May 3, 2021 /PRNewswire/ The Aesthetic Surgery Education and Research Foundation (ASERF) announced the election of Louis L. Strock, MD, a plastic surgeon practicing in Fort Worth, Texas as its new President. Dr. Strock is an aesthetic and reconstructive plastic surgeon certified by the American Board of Plastic Surgery. ASERF is the philanthropic research and education arm of
The Aesthetic Society. As President of ASERF, Dr. Strock plans to leverage research and technology advancements from the Aesthetic One app and Aesthetic Neural Network (ANN) to gain deeper insights for both doctors and patients.
Charlie Teo Foundation grant to fund key research of new Pharmaxis Ltd drug to tackle brain cancer proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer
Study to be Conducted at The University of Texas MD Anderson Cancer Center Mereo BioPharma Group plc; Cancer Focus Fund LONDON, UNITED KINGDOM
LONDON and REDWOOD CITY, Calif. and HOUSTON, Texas, April 30, 2021 (GLOBE NEWSWIRE) Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to provide funding and clinical expertise to advance promising cancer therapies, today announced a partnership to evaluate Mereo’s lead anti-TIGIT therapeutic antibody candidate, etigilimab, in clear cell ovarian cancer, a rare cancer that accounts for approximately 5–10% of all ovarian ca
Why mRNA COVID-19 vaccines might unlock the key to treating cancer and other deadly diseases
elisfkc2 / Flickr / CC BY-SA 2.0
TORONTO, Ontario (CTV Network) The mRNA technology used for the Pfizer-BioNTech and Moderna vaccines has been hailed as a medical breakthrough in the fight against COVID-19.
The vaccines’ high efficacy against SARS-CoV-2, the virus which causes COVID-19, their safety in clinical trials, and how quickly they were produced has generated much excitement within the scientific community.
And while the technology is hardly new – it’s been decades in the making – the pandemic fast-tracked its development thanks to increased interest and funding, and accelerated regulatory approvals.